Sequence by WeightWatchersvsRo Body

Sequence is a telehealth platform, not a drug. You complete an online health-history questionnaire, then have a video visit with a board-certified clinician who decides whether a prescription weight-loss medication is safe and appropriate for you. The medications prescribed are mostly GLP-1 (and dual GLP-1/GIP) receptor agonists such as semaglutide (Wegovy), tirzepatide (Zepbound), and liraglutide (Saxenda); non-GLP-1 options like metformin or naltrexone/bupropion may also be used when appropriate. These drugs mimic gut hormones that slow stomach emptying, blunt appetite, and increase fullness, so many people eat less without constant hunger. Layered on top is WeightWatchers' behavioral program: the Points food system, dietitian access, fitness guidance, and a GLP-1 Success Program focused on protein intake and muscle preservation during weight loss.

Ro Body itself is a service layer, not a drug. You complete an online intake, a licensed clinician reviews your history, and, if appropriate, prescribes an FDA-approved GLP-1 (or dual GLP-1/GIP) medication such as Wegovy or Ozempic (semaglutide) or Zepbound (tirzepatide). These medicines mimic gut hormones that signal fullness to the brain, slow stomach emptying, and reduce appetite and food cravings, so most people eat less and lose weight. Ro layers on monthly provider check-ins, unlimited messaging, registered-nurse coaching, a behavior-change curriculum, dose-titration support, and an insurance concierge that submits prior authorizations to help you pursue coverage.

Real-world and trial evidence for these medications is genuinely strong, though the platform-specific figures should be read with caution. A 2024 retrospective analysis in the journal Obesity (Ard et al.) of the WeightWatchers/Sequence telehealth program reported that, among patients with complete data at 12 months, average weight loss was about 19.4% of initial body weight, with roughly 21.2% on tirzepatide and the semaglutide formulations (Wegovy and Ozempic) in the mid-teens, broadly 13 to 15 percent. A key caveat: of the 53,590 patients who started treatment, only about 6,089 had complete 12-month data, so these completer averages likely overstate typical results because people who stopped early or regained are underrepresented. These outcomes are broadly in line with the pivotal drug trials: semaglutide 2.4 mg produced about 14.9% mean weight loss over 68 weeks in STEP 1 (NEJM 2021); tirzepatide produced roughly 20.9% (15 mg, treatment-regimen estimand) and up to about 22.5% over 72 weeks in SURMOUNT-1 (NEJM 2022); and in the head-to-head SURMOUNT-5 trial (NEJM 2025) tirzepatide outperformed semaglutide, about 20.2% versus 13.7% at 72 weeks. Individual results vary widely and depend heavily on staying on the medication and engaging with the program.

Ro cites average weight loss of roughly 15% of body weight over a year, a figure that tracks the medications' pivotal trials rather than a separate Ro study. In the STEP 1 trial (Wilding et al., NEJM 2021; n=1,961), once-weekly semaglutide 2.4 mg (Wegovy) produced a mean 14.9% weight loss at 68 weeks versus 2.4% for placebo, with 86.4% of participants losing at least 5%. For tirzepatide (Zepbound), the SURMOUNT-1 trial (Jastreboff et al., NEJM 2022; n=2,539) showed mean losses of 16.0%, 21.4%, and 22.5% at the 5, 10, and 15 mg doses versus 2.4% for placebo over 72 weeks. These results reflect the medication combined with lifestyle change, and weight tends to return after stopping. Individual results vary.

The most common side effects come from the medications, not the platform, and are mostly gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort, usually worst when starting or increasing the dose and often easing over time. Slow dose titration and dietary adjustments can help. Less common but serious risks include an FDA boxed warning for thyroid C-cell tumors (based on rodent studies; human risk is not established), along with reported cases of pancreatitis, gallbladder disease and gallstones, kidney injury from dehydration, and, with tirzepatide, possible reduced absorption of oral contraceptives. Rapid weight loss can also cause loss of muscle mass, which the WW GLP-1 Success Program tries to counter with high-protein and strength guidance. Seek prompt medical attention for severe or persistent abdominal pain, persistent vomiting, or signs of an allergic reaction, and report concerning symptoms to your care team. This is not a complete list of side effects.

The most common side effects come from the GLP-1 medication, not the platform: nausea, vomiting, diarrhea, constipation, stomach pain, indigestion, gas, fatigue, and headache. These are usually mild to moderate, worst when starting or raising the dose, and tend to ease over time. Serious but less common risks include pancreatitis (severe, persistent abdominal pain), gallbladder problems and gallstones, kidney problems from dehydration, low blood sugar (especially if combined with insulin or a sulfonylurea), and, rarely, serious allergic reactions. Wegovy, Ozempic, and Zepbound carry an FDA boxed warning for thyroid C-cell tumors seen in rodents; whether this risk applies to humans is unknown. Stop the medication and seek care for severe stomach pain.

As of 2026, WW Clinic / Med+ membership is commonly advertised at about $25/month for the first two to three months, then roughly $74/month for the remainder of a 12-month plan, with month-to-month options reported around $149/month. Membership covers clinician visits, insurance coordination, labs, coaching, and the WW app, but the medication is billed separately. List prices for brand-name GLP-1s can run roughly $1,000 to $1,350 per month, but few people pay that: WeightWatchers and the manufacturers offer cash-pay programs that are far lower (for example, Novo Nordisk's self-pay Wegovy oral tablet has been offered near $149/month and WW has advertised cash-pay injectable starter pricing well under list), and commercial insurance, where it covers weight-loss GLP-1s, can drop out-of-pocket costs to roughly $25 to $150/month. Coverage and savings eligibility vary widely, so verify your specific plan and compare WW's drug pricing against pharmacy and manufacturer options before committing.

As of 2026, Ro Body membership is about $45 the first month and roughly $145/month after, and is lower if you prepay annually (Ro's own site has listed figures closer to $39 first month and $149/month month-to-month, so confirm the current price at checkout). The membership fee is generally not covered by insurance, though HSA/FSA funds may apply. Medication is billed separately and is the bigger variable. If your insurance covers brand Wegovy or Zepbound, savings cards can bring your out-of-pocket cost down to as little as $0 to $25/month. Without coverage, cash-pay options through programs like NovoCare and LillyDirect have run roughly $300 to $500/month for self-pay vials or pens in 2026 (with introductory pricing as low as ~$199 for early Wegovy fills), and Ro advertises additional prepay savings. Confirm your specific drug, dose, and coverage before committing, because total out-of-pocket varies widely.

The program is designed for US adults who meet clinical criteria for anti-obesity medication, typically a BMI of 30 or higher, or 27 or higher with a weight-related condition such as type 2 diabetes, high blood pressure, or sleep apnea. The clinician makes the final call after reviewing your history and, in many cases, lab work. GLP-1 medications are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2), and they should not be used in pregnancy or by people with a prior serious hypersensitivity reaction to the drug. People with a history of pancreatitis, gallbladder disease, gastroparesis, kidney problems, or diabetic retinopathy need careful evaluation. The program is not a substitute for in-person care and is not appropriate for those seeking medication without medical oversight.

Generally for US adults with obesity (BMI 30+) or overweight (BMI 27+) plus a weight-related condition such as type 2 diabetes, high blood pressure, or high cholesterol, who want medication-supported weight loss. Not appropriate for, and the underlying GLP-1 drugs are contraindicated in, anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or with a prior serious hypersensitivity reaction to the drug. Not for use in pregnancy or breastfeeding, and clinicians use caution with a history of pancreatitis, gallbladder disease, or severe gastrointestinal disorders. A clinician makes the final call, and some applicants are found ineligible.